EZH2 and epithelioid sarcoma: In 2020, the FDA approved the EZH2 inhibitor tazemetostat (Figure 1) as a first-in-class drug for the treatment of advanced epithelioid sarcoma or relapsed/refractory EZH2-mutated follicular lymphoma [18].